Literature DB >> 30211182

Advances in resistant hypertension.

David A Calhoun1.   

Abstract

Entities:  

Year:  2018        PMID： 30211182      PMCID： PMC6123198          DOI： 10.21037/atm.2018.07.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.

Authors:  Rosa L de Jager; Erik M van Maarseveen; Michiel L Bots; Peter J Blankestijn
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

2.  Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Maria C Acelajado; Roberto Pisoni; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2015-05-18       Impact factor: 10.190

3.  Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.

Authors:  Hemal Bhatt; Mohammed Siddiqui; Eric Judd; Suzanne Oparil; David Calhoun
Journal:  J Am Soc Hypertens       Date:  2016-03-30

4.  Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Authors:  Brent M Egan; Yumin Zhao; Jiexiang Li; W Adam Brzezinski; Thomas M Todoran; Robert D Brook; David A Calhoun
Journal:  Hypertension       Date:  2013-08-05       Impact factor: 10.190

5.  Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.

Authors:  E Florczak; A Prejbisz; E Szwench-Pietrasz; P Sliwiński; P Bieleń; A Klisiewicz; I Michałowska; E Warchoł; M Januszewicz; M Kała; A Witkowski; A Więcek; K Narkiewicz; V K Somers; A Januszewicz
Journal:  J Hum Hypertens       Date:  2013-05-23       Impact factor: 3.012

6.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

7.  Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.

Authors:  Alejandro Velasco; Mohammed Siddiqui; Eric Kreps; Pavani Kolakalapudi; Tanja Dudenbostel; Garima Arora; Eric K Judd; Sumanth D Prabhu; Steven G Lloyd; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2018-06-04       Impact factor: 10.190

Review 8.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 9.897

9.  Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Authors:  Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-11       Impact factor: 32.069

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
  10 in total
  1 in total

Review 1.  Recent advances in understanding and managing resistant/refractory hypertension.

Authors:  Michael Doumas; Konstantinos P Imprialos; Manolis S Kallistratos; Athanasios J Manolis
Journal:  F1000Res       Date:  2020-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.